Correction

Alternative breast cancer drug shows promise

BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7517.622 (Published 15 September 2005) Cite this as: BMJ 2005;331:622

In this News Extra article by Allison Barrett on bmj.com, we wrongly said that anastrozole is licensed only for treating women who are unable to take tamoxifen (bmj.com 2005, 13 Aug, http://bmj.bmjjournals.com/cgi/content/full/331/7513/368-a). In fact, in July 2005 anastrozole was licensed in the United Kingdom for the adjuvant treatment of postmenopausal women with hormone receptor positive early invasive breast cancer—an extension of its previous licence, which allowed its use only in women unable to take tamoxifen. However, the National Institute for Health and Clinical Excellence has not yet made recommendations on its use, although it is currently reviewing hormonal treatments for breast cancer and is expected to report its recommendations in November 2006.

Footnotes

View Abstract